Helicon

Helicon Therapeutics (operating at helicontx.com) is a San Diego-based biotechnology company developing RNA interference (RNAi) medicines for neurodegenerative diseases. The company applies RNAi technology — which silences disease-causing genes at the RNA level — to address conditions such as Alzheimer's disease and other neurological disorders where conventional small-molecule approaches have limited efficacy. Helicon's scientific team includes researchers with expertise in molecular biology and gene silencing, including scientists focused on RNAi delivery and target validation for the central nervous system. The company's website is in early-stage development (showing a coming-soon placeholder), consistent with its pre-clinical or early-stage status. Helicon Therapeutics operates in the broader RNAi therapeutics sector, which has seen significant validation through approved products from companies like Alnylam Pharmaceuticals, and positions itself as a next-generation RNAi medicine developer specifically targeting the neurodegeneration space.